Thierry, what do you see as the main achievements of QIAGEN in 2025?
What stands out most is execution and consistency, especially during a year that included a smooth transition to a new organizational structure.
QIAGEN delivered on its commitments for sales growth, profitability and product launches in a market that remained volatile and cautious.
That matters, but it is not the full story. For six consecutive years, QIAGEN has met or exceeded its targets quarter after quarter. That kind of consistency does not happen by chance. It reflects preparation, discipline and the daily efforts of QIAGENers around the world.
It was a year defined by steady professional execution. That is what builds credibility and trust over time.
As we move ahead in 2026, how would you describe QIAGEN’s position in today’s world?
QIAGEN has a clear mission to advance science and improve healthcare through its portfolio of solutions for molecular research and clinical diagnostics. That purpose shapes how the company invests and how it prioritizes.
The portfolio is built around pillars where QIAGEN can lead and take the top 1–3 market positions. Sample technologies remain the first and most critical step in the biology workflow, enabling access to DNA and RNA.
QuantiFERON continues to set the standard in latent TB testing. At the same time, strong positions are being built in digital PCR with QIAcuity, in syndromic testing with QIAstat-Dx and in bioinformatics through QIAGEN Digital Insights.
This focus is complemented by balance. QIAGEN operates across Life Sciences and clinical diagnostics and across all major regions of the world. And with around 90% of sales generated from recurring consumables that keep laboratories running, QIAGEN remains resilient even in this uncertain environment. We are building resilient and competitive ecosystems where we bring together the main components of the value chain, from instruments to consumables to gain access to biology through to increasingly AI-driven data analytics.
In a world where volatility has become normal, this combination of focus and balance provides stability and room to invest for the long term.
You often speak about focus. What does that really mean in practice?
Focus means making clear choices.
Not every opportunity fits the strategy. A company of our size cannot pursue everything. Resources are directed toward areas where capabilities reinforce each other and where differentiation is clear. The objective is to build and defend leadership positions.
In 2024, deliberate decisions were made to sharpen the portfolio further, including the discontinuation of the NeuMoDx clinical PCR system in light of market trends. That discipline continues today. The portfolio must continuously earn its place. Continuous improvement requires honest review and the willingness to adjust when needed.
Focus is not a slogan. It shapes research priorities, commercial investment and how we allocate capital every day.
Organic investment clearly plays a central role. How do you sustain innovation with so many scientific advances these days while remaining disciplined?
Organic growth is the backbone of QIAGEN’s strategy.
The company continues to invest around 9–10% of sales into research and development. That sustained commitment reflects a long-term view that innovation must be both differentiated and profitable.
The results are visible across the portfolio. In Sample technologies, three new automation platforms are being introduced with QIAsymphony Connect, QIAsprint Connect and QIAmini. Menu expansion continues across QIAstat-Dx and QIAcuity. Development is advancing on the fifth generation of QuantiFERON.
These investments ensure that the portfolio evolves with scientific progress and customer needs while remaining aligned with strategic priorities.
Beyond organic growth, how do acquisitions fit into the QIAGEN strategy?
Acquisitions are pursued selectively and with discipline.
The objective is to strengthen existing pillars and expand capabilities where QIAGEN already has a strong foundation. Transactions must be strategically aligned, commercially synergistic and create value within a reasonable timeframe.
Two acquisitions illustrate that approach. Parse Biosciences expands capabilities in single cell analysis, complementing our strengths in Sample technologies and bioinformatics and opening up new opportunities in research and clinical applications.
Genoox strengthens QIAGEN Digital Insights. The Franklin platform enhances clinical interpretation of genomic data with advanced analytics and artificial intelligence.
These additions reinforce leadership positions and complement organic investment, ensuring growth remains focused and sustainable.
Markets remain uncertain. What mindset guided the company through that environment?
The mindset is to remain calm, disciplined and forward-looking.
Volatility has become part of the environment. Customers are cautious and capital spending cycles fluctuate. The response is not to overreact but to concentrate, execute on what can be controlled and always proactively prepare for the future.
That means consistent quarterly execution, continued investment in innovation and responsible capital allocation. Confidence comes from preparation and from people.
The resilience and professionalism of QIAGENers worldwide remain decisive strengths.
Finally, on a personal note, as you prepare to step down as CEO, what do you take away from your time at QIAGEN?
Above all, gratitude and respect.
QIAGEN builds on more than four decades of scientific excellence, but what defines the company is its culture of empowering action, especially among those closest to customers. Our people are translating strategy into action every day.
That culture was visible during the COVID-19 pandemic. At a time of extraordinary pressure, QIAGENers around the world stepped up to ensure that no country was left behind. Supply chains were challenged and demand was unprecedented, yet teams acted with urgency and responsibility to support public health systems and laboratories globally.
QIAGEN products will continue to stand at the forefront of advancing science and improving healthcare.
I will always have a deep respect and passion for QIAGEN and the QIAGENers. I tried my best and now it is time to welcome new ideas.
I have strong confidence in the path ahead and deep appreciation for the opportunity to have been part of this truly remarkable company.
